• Atopobium vaginae;
  • bacterial vaginosis;
  • metronidazole;
  • resistance;
  • secnidazole


  1. Top of page
  2. Abstract
  3. Transparency Declaration
  4. References

Clin Microbiol Infect 2010; 16: 470–472


Bacterial vaginosis is a polymicrobial syndrome. The most important marker for bacterial vaginosis is the presence of Gardnerella vaginalis and Atopobium vaginae. In this study, the in vitro susceptibilities to metronidazole and secnidazole of 16 strains of A. vaginae were tested with the agar dilution method. We observed an MIC range for metronidazole of 4–64 mg/L (MIC50, 8 mg/L; MIC90, 32 mg/L) and an MIC range for secnidazole of 4–128 mg/L (MIC50, 16 mg/L; MIC90, 64 mg/L). According to these findings, we can conclude that the activity of secnidazole is similar to that of metronidazole.

Bacterial vaginosis (BV) is a polymicrobial syndrome in which the lactobacilli of the normal microflora are overgrown by Gram-positive and Gram-negative bacteria and for which high concentrations of Gardnerella vaginalis and, recently, Atopobium vaginae have been recognized as important microbiological markers [1,2], whereby a high concentration of A. vaginae is a better marker than a high concentration of G. vaginalis [2,3]. Both species are frequently found together in the biofilm formed in BV [4]. Metronidazole and clindamycin are the preferred treatment regimens. In this study, the in vitro activities of secnidazole against members of the Atopobium group were tested.

Secnidazole is a member of the family of 5-nitro-imidazoles, as is metronidazole. Secnidazole could be a valuable alternative for metronidazole, owing to a longer half-life and fewer side effects [5]. The longer half-life makes single-dose applications possible, which could avoid treatment failures caused by patient compliance. Previously, the susceptibility to secnidazole was determined by Dubreuil et al. [6] for several strictly anaerobic bacteria, including bacteria involved in BV, although A. vaginae was not included. High MIC values of A. vaginae for metronidazole have been reported [7,8].

For this study, 16 strains of A. vaginae, two strains of Atopobium parvulum and one strain each of Atopobium rimae and Atopobium minutum were tested. Six strains of A. vaginae (CCUG  44258, CCUG  42099, CCUG  44125, CCUG  44061 and CCUG  38953T) and one strain each of A. minutum (CCUG  31167), A. rimae (CCUG  31168) and A. parvulum (CCUG  32760) were obtained from the Culture Collection of the University of Göteborg. All other strains were clinical vaginal isolates obtained during studies at the Laboratory Bacteriology Research from 2003 until 2006. In addition, two quality control strains were included, i.e. Bacteriodes thetaiotaomicron CCUG  34778 and Bacteriodes fragilis CCUG  4856.

For both metronidazole (Dr Ehrenstorfer, Augsburg, Germany) and secnidazole (Ethypharm, Houdan, France), a stock solution of 5120 mg/L was prepared. Secnidazole was dissolved in dimethylsulphoxide (DMSO), and the DMSO concentration was afterwards adjusted to 10% with sterile distilled water. Two-fold dilution series in distilled water were made for both antibiotics, as previously described [9].

One millilitre of each dilution was incorporated in 19 mL of Mueller–Hinton agar, supplemented with 5% sterile defibrinated sheep blood (E&O Laboratories, Bonnybridge, UK) at 50°C. Plates contained Mueller–Hinton agar with serial two-fold dilutions of antimicrobial agents between 256 and 0.5 mg/L, and two negative control plates to which 1 mL of distilled water or 1 mL of a 10% DMSO solution was added. The plates were dried with open lids for 1 h and stored at 4°C. Plates were pre-incubated for 5 h in an anaerobic workstation (BugBoxPlus; LED techno, Heusden-Zolder, Belgium).

Strains were cultured on Mueller–Hinton agar + 5% sheep blood (Becton Dickinson, Erembodegem, Belgium) for 72 h in an anaerobic workstation (BugBoxPlus; LED techno) at 37°C. Strains were harvested and suspended in sterile saline (0.9% NaCl) at a density equal to a McFarland standard (Biomérieux, Boxtel, The Netherlands) of 0.5. Immediately after inoculation of the strains with a Steers replicator (Mast Systems, London, UK), plates were incubated in the anaerobic workstation for 72 h at 37°C.

The MIC values for metronidazole and secnidazole were, respectively, 1 and 2 mg/L for both control strains, B. fragilis CCUG  4856 and B. thetaiotaomicron CCUG  34778; these values are within the expected range. Both negative control plates showed dense growth for all strains, and no difference was seen between the negative control plates containing 0.5% DMSO and distilled water. For the 16 strains of A. vaginae, we observed an MIC range for metronidazole of 4–64 mg/L (MIC50, 8 mg/L; MIC90, 32 mg/L) and an MIC range for secnidazole of 4–128 mg/L (MIC50, 16 mg/L; MIC90, 64 mg/L). The results for all the strains are listed in Table 1.

Table 1.   Susceptibilities of Atopobium strains to metronidazole and secnidazole
SpeciesStrainMetronidazole MIC (mg/L)Secnidazole MIC (mg/L)
  1. T, type strain.

Atopobium minutum CCUG  31167≤0.51
Atopobium parvulum CCUG  32760≤0.5≤0.5
Atopobium parvulum TiG2922
Atopobium rimae CCUG  31168≤0.50.5
Atopobium vaginae CCUG  38953T1616
Atopobium vaginae CCUG  4209984
Atopobium vaginae CCUG  44061816
Atopobium  vaginae CCUG  441161616
Atopobium vaginae CCUG  44125816
Atopobium vaginae CCUG  44258416
Atopobium vaginae FB010-0664128
Atopobium vaginae FB101-3C88
Atopobium vaginae FB106B816
Atopobium vaginae FB130-CNAB-2aD1664
Atopobium vaginae FB145-BA-14A816
Atopobium vaginae FB158-CNA-2C816
Atopobium vaginae FB160-CNAB-788
Atopobium vaginae PB2003/009-T1-41632
Atopobium vaginae PB2003/017-T1-23232
Atopobium vaginae PB2003/189-T1-488
Bacteroides fragilis CCUG  485611
Bacteroides thetaiotaomicron CCUG  3477822

This study was carried out to compare the in vitro MIC values of Atopobium strains for secnidazole in comparison with metronidazole. It is difficult to link these values to susceptibility breakpoints, for several reasons. Different authorities (CLSI, EUCAST) have determined breakpoints for resistance for metronidazole, but not yet for secnidazole. CLSI breakpoints are general for all nitro-imidazole molecules, but EUCAST criteria are only specified for metronidazole. In addition, not much is known about the pharmacokinetics of these compounds in the vagina.

With use of a topical treatment, high concentrations of metronidazole can be achieved, although the most common administration route is the oral one. Davis et al. [10] reported that a maximum concentration of 26 mg/L could be reached in the vaginal fluid 6 h after oral administration of 2 g of metronidazole, at which time it equals the serum concentration. These data correspond to those of Matilla et al. [11], showing that the maximal serum concentration of 9.4 mg/L is reached 1.9 h after oral administration of 500 mg of metronidazole. The half-life of metronidazole ranges from 7 to 9.7 h, in contrast to the half-life of secnidazole, which ranges from 17 to 28.8 h with a Cmax of 35.7–46.3 mg/L for a 2-g dose [12]. Recent studies confirm these previous results (B. Dickey, 2009, to be published). Therefore, it seems appropriate that EUCAST and CLSI should propose new criteria for secnidazole in accordance with these findings.

Bradshaw et al. [2] reported that, despite a significant reduction of A. vaginae numbers after treatment with oral metronidazole (400 mg twice daily for 7 days), BV cases with both A. vaginae and G. vaginalis had much higher rates of recurrent BV (83%) than those with G. vaginalis only (38%). This could possibly be explained by acquired resistance, e.g. through the presence and activation of nim genes [13] or by the biofilm that is present in BV [4]. According to a recent meta-analysis of published results [14], treatment of both partners may be important for the eradication of BV.

Transparency Declaration

  1. Top of page
  2. Abstract
  3. Transparency Declaration
  4. References

E. De Backer is supported by the Institute for the Promotion of Innovation through Science and Technology in Flanders (IWT-Vlaanderen). The study was sponsored by IPRAD Laboratories, Paris, France.


  1. Top of page
  2. Abstract
  3. Transparency Declaration
  4. References
  • 1
    Verhelst R , Verstraelen H , Claeys G et al. Cloning of 16S rRNA genes amplified from normal and disturbed vaginal microflora suggests a strong association between Atopobium vaginae, Gardnerella vaginalis and bacterial vaginosis . BMC Microbiol 2004 ; 4 : 16 .
  • 2
    Bradshaw CS , Tabrizi SN , Fairley CK , Morton AN , Rudland E , Garland SM . The association of Atopobium vaginae and Gardnerella vaginalis with bacterial vaginosis and recurrence after oral metronidazole therapy . J Infect Dis 2006 ; 194 : 828836 .
  • 3
    Menard JP , Fenollar F , Henry M , Bretelle F , Raoult D . Molecular quantification of Gardnerella vaginalis and Atopobium vaginae loads to predict bacterial vaginosis . Clin Infect Dis 2008 ; 47 : 3343 .
  • 4
    Swidsinski A , Mendling W , Loening-Baucke V et al. Adherent biofilms in bacterial vaginosis . Obstet Gynecol 2005 ; 106 : 10131023 .
  • 5
    Gillis JC , Wiseman LR . Secnidazole. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis . Drugs 1996 ; 51 : 621638 .
  • 6
    Dubreuil L , Calvet L , Behra J . Le secnidazole: activite antibactérienne sur les anaérobies stricts . Antibiotiques 2005 ; 7 : 239246 .
  • 7
    De Backer E , Verhelst R , Verstraelen H et al. Antibiotic susceptibility of Atopobium vaginae . BMC Infect Dis 2006 ; 6 : 51 .
  • 8
    Ferris MJ , Masztal A , Aldridge KE , Fortenberry JD , Fidel PL Jr , Martin DH . Association of Atopobium vaginae, a recently described metronidazole resistant anaerobe, with bacterial vaginosis . BMC Infect Dis 2004 ; 4 : 5 .
  • 9
    Ericsson HM , Sherris JC . Antibiotic sensitivity testing. Report of an international collaborative study . Acta Pathol Microbiol Scand B Microbiol Immunol 1971 ; 217 ( suppl 217 ): S1S90
  • 10
    Davis B , Glover DD , Larsen B . Analysis of metronidazole penetration into vaginal fluid by reversed-phase high-performance liquid chromatography . Am J Obstet Gynecol 1984 ; 149 : 802803 .
  • 11
    Mattila J , Mannisto PT , Mantyla R , Nykanen S , Lamminsivu U . Comparative pharmacokinetics of metronidazole and tinidazole as influenced by administration route . Antimicrob Agents Chemother 1983 ; 23 : 721725 .
  • 12
    Lamp KC , Freeman CD , Klutman NE , Lacy MK . Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials . Clin Pharmacokinet 1999 ; 36 : 353373 .
  • 13
    Theron MM , Janse Van Rensburg MN , Chalkley LJ . Nitroimidazole resistance genes (nimb) in anaerobic gram-positive cocci (previously Peptostreptococcus spp.) . J Antimicrob Chemother 2004 ; 54 : 240242 .
  • 14
    Fethers KA , Fairley CK , Hocking JS , Gurrin LC , Bradshaw CS . Sexual risk factors and bacterial vaginosis: a systematic review and meta-analysis . Clin Infect Dis 2008 ; 47 : 14261435 .